Your browser doesn't support javascript.
loading
Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation.
Sandomenico, Annamaria; Ruggiero, Alessia; Iaccarino, Emanuela; Oliver, Angela; Squeglia, Flavia; Moreira, Miguel; Esposito, Luciana; Ruvo, Menotti; Berisio, Rita.
Afiliação
  • Sandomenico A; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Ruggiero A; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Iaccarino E; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Oliver A; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Squeglia F; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Moreira M; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Esposito L; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Ruvo M; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
  • Berisio R; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
Int J Mol Sci ; 24(10)2023 May 10.
Article em En | MEDLINE | ID: mdl-37239905
ABSTRACT
CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericidal pore-forming toxin of the innate immune system. In addition, several pathogenic viruses, including HIV-1, escape complement-mediated virolysis by incorporating this complement inhibitor in their own viral envelope. This makes human pathogenic viruses, such as HIV-1, not neutralised by the complement in human fluids. CD59 is also overexpressed in several cancer cells to resist the complement attack. Consistent with its importance as a therapeutical target, CD59-targeting antibodies have been proven to be successful in hindering HIV-1 growth and counteracting the effect of complement inhibition by specific cancer cells. In this work, we make use of bioinformatics and computational tools to identify CD59 interactions with blocking antibodies and to describe molecular details of the paratope-epitope interface. Based on this information, we design and produce paratope-mimicking bicyclic peptides able to target CD59. Our results set the basis for the development of antibody-mimicking small molecules targeting CD59 with potential therapeutic interest as complement activators.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas do Sistema Complemento / HIV-1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas do Sistema Complemento / HIV-1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália